insulin

Overview

Insulin is a 51-amino acid peptide hormone synthesized and secreted by the beta cells of the pancreatic islets of Langerhans. It plays a central role in carbohydrate metabolism and energy homeostasis by facilitating the uptake and utilization of blood glucose in peripheral tissues, particularly muscle and adipose tissue. Beyond its canonical metabolic functions, insulin has broader physiological effects throughout the body, including roles in blood pressure regulation through neural mechanisms and cellular proliferation signaling. The hormone operates through the insulin receptor, a transmembrane tyrosine kinase that triggers multiple intracellular signaling cascades upon ligand binding. Insulin is one of the most important therapeutic agents in modern medicine, essential for managing diabetes mellitus—a group of metabolic disorders characterized by chronic hyperglycemia and impaired glucose homeostasis. The clinical applications of insulin span from acute management of diabetic ketoacidosis to long-term glycemic control in both type 1 and type 2 diabetes, with therapeutic strategies now encompassing multiple formulations including human insulin and engineered insulin analogues that modulate absorption kinetics and duration of action.

Recent Publications Summary

Recent research has explored insulin's multifaceted role in diabetes management, from optimizing treatment timing to developing novel formulation strategies. In type 2 diabetes patients, the choice of second-line antidiabetic medication—including insulin secretagogues, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors—significantly influences the timing of insulin initiation 42563367Aug.

Multiple therapeutic approaches have focused on improving insulin efficacy and patient outcomes. Comparative studies found that insulin analogues, when used in children and adolescents with type 1 diabetes, produced superior glycemic control compared with human insulin, with extended time spent within target glucose ranges and reduced hypoglycemic episodes 42460849Jul. To address local insulin aggregation and fibrillation at injection sites, researchers have explored phytochemical complexation; both curcumin cysteine complex and rosmarinic acid demonstrated dose-dependent inhibition of insulin fibrillation in vitro and enhanced therapeutic efficacy in vivo models 42331169Jun. Structural analysis of commercial insulin preparations using solid-state nuclear magnetic resonance spectroscopy revealed distinct conformational differences across different formulation types 42206399May. Emerging delivery innovations include glucose-responsive microneedle patches incorporating dual nanoparticle-hydrogel systems that enable coordinated release of insulin alongside exendin-4 for enhanced glycemic control 42148925May, and genetically engineered Spirulina designed as an oral delivery vehicle for recombinant human insulin to overcome gastrointestinal barriers 42093398May.

Physiological investigations have clarified how exercise and physical activity modulate insulin's systemic effects. Acute treadmill exercise was shown to reduce blood pressure elevations typically induced by intranasal insulin in aging adults with cardiometabolic risk 42295834Jun. Conversely, meta-analysis evidence indicates that prolonged bed rest increases fasting insulin concentrations and insulin resistance markers 41853886Mar.

Assessment of insulin resistance through surrogate biomarkers remains clinically relevant for diabetes risk prediction. Comparative analysis of 18 surrogate indexes for insulin resistance demonstrated that indexes calculated from oral glucose tolerance tests—particularly the Matsuda index—provided superior predictive performance for identifying type 2 diabetes risk 41805838Mar.

What Changes, What Holds

1. Second-line drug choice influences insulin initiation timing in type 2 diabetes
NEW DIRECTION Insulin secretagogues, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors affect when insulin becomes necessary 42563367Aug. The Overview addresses insulin's therapeutic role without discussing treatment algorithms or sequencing with other antidiabetic drugs, marking a gap in clinical guidance for type 2 diabetes management.

2. Novel oral and transdermal delivery bypass insulin's injection requirement
NEW DIRECTION Glucose-responsive microneedle patches co-delivering insulin and exendin-4 42148925May and genetically engineered Spirulina enabling oral recombinant insulin absorption 42093398May create non-parenteral routes. The Overview enumerates "multiple formulations" but not non-injection delivery; injection-site fibrillation prevention via phytochemical complexes also surfaces as a previously uncharacterized problem 42331169Jun.

3. exercise attenuates while bed rest amplifies insulin's metabolic effects
NEW DIRECTION Acute treadmill exercise reduces blood pressure elevations otherwise induced by intranasal insulin in aging 42295834Jun; prolonged bed rest increases fasting insulin and insulin resistance markers 41853886Mar. The Overview notes insulin's blood pressure regulation role but omits how physical activity state reciprocally modulates these systemic effects.

4. Glucose tolerance-derived indexes predict type 2 diabetes risk better than fasting measures
NEW DIRECTION Matsuda index from oral glucose tolerance tests outperforms fasting-based surrogates across 18 compared indexes for identifying type 2 diabetes risk 41805838Mar. The Overview identifies insulin resistance as a feature of impaired homeostasis without discussing assessment methods or prediction approaches.

Overview update candidates: Novel glucose-responsive microneedle and oral Spirulina insulin delivery; Matsuda index superiority for type 2 diabetes risk stratification.